Rituximab is useful in the treatment of Felty's syndrome.

Abstract

Felty's syndrome is regarded as a severe variant of rheumatoid arthritis (RA) that develops in less than 1% of patients with RA. It consists of a triad of RA, splenomegaly, and leukopenia, which tends to develop after a long course of RA. Treatment of neutropenia is mainly comprised of disease-modifying antirheumatic drugs including methotrexate, hydroxychloroquine, auronofin, penicillamine, glucocorticoids, and granulocyte monocyte colony stimulating factor. Recently, there has been a growing interest in the biologic agent rituximab in the treatment of Felty's syndrome. To our knowledge, only one previous case of rituximab being beneficial in the treatment of Felty's syndrome has been reported. We report the case of a 60-year-old man with Felty's syndrome in whom treatment with rituximab led to a sustained neutrophil response and marked symptomatic improvement in the form of decrease in the size of rheumatoid nodules and better pain control.

• Authors: Preeti A Chandra, Yevgeniya Margulis, Carl Schiff
• Journal: American journal of therapeutics (Am J Ther) 2008 Jul-Aug Vol. 15 Issue 4 Pg. 321-2 ISSN: 1536-3686 [Electronic] United States
• PMID: 18645332 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antirheumatic Agents
• Rituximab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antirheumatic Agents (therapeutic use)
• Felty Syndrome (drug therapy, immunology, physiopathology)
• Humans
• Male
• Middle Aged
• Neutrophils (drug effects, metabolism)
• Pain (drug therapy, etiology)
• Risk Factors
• Rituximab